In addition to PD-L1 expression, high MSI, dMMR, and high TMB which have been approved by the Food and Drug Administration as biomarkers of immunotherapy [30], our results further suggest that the indel ratio may be associated with a response to PD-1 blockade for ICC patients. Here, CD274 is linked to intrahepatic cholangiocarcinoma.